novo nordisk is cutting prices on its popular glp-1 drugs. Novo, Lilly Shares Drop as Trump Promises $150 Ozempic Novo Nordisk cuts GLP-1 prices

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease

Potential Reasons to Consider Saxenda Insurance considerations: Your insurance covers Saxenda but not semaglutide Prior authorization requirements differ Step therapy requires trying Saxenda first Previous experience: Youve had success with Saxenda before You know you tolerate liraglutide well Youre continuing existing treatment Specific medical situations: Your provider has specific reasons to prefer liraglutide You have conditions that favor one medication over the other Part of a comprehensive treatment plan designed around liraglutide Personal preference: You strongly prefer daily dosing (some patients find this easier to remember) You want the FDA-approved weight loss indication specifically When Semaglutide Is Almost Always Better For most patients, semaglutide is preferable: Greater effectiveness: Nearly twice the weight loss makes a substantial difference in outcomes

Zhang Q, Wang L, Wang S, Cheng H, Xu L, Pei G, Wang Y, Fu C, Jiang Y, He C, et al

Funding support This work is the result of NIH funding, in whole or in part, and is subject to the NIH Public Access Policy

This gives certainty regarding its clinical application (104)

It is widely prescribed with a high level of confidence by physicians given the evidence that is available in the treatment of T2DM and obesity, along with a strong clinical package and regulatory support